GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

FEED · Sep 30, 2024

ENvue Medical, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001493152-24-045726General Corporate
Capex intensity25thOwn-history percentile · N=8
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

0.00% · OPTIONAL · VALID

Operating cash generation50thOwn-history percentile · N=8
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-222.34% · OPTIONAL · VALID

Revenue growthRAWCurrent state valid · history insufficient
Evidence method

Yoy · gp.fundamentals.revenue

-17.90% · CORE · NOT_ENOUGH_HISTORY

Inventory pressure50thOwn-history percentile · N=8
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

598.40% · OPTIONAL · VALID

Gross margin13thOwn-history percentile · N=8
Evidence method

Level · gp.fundamentals.gross_margin

35.37% · CORE · VALID

Operating margin50thOwn-history percentile · N=8
Evidence method

Level · gp.fundamentals.operating_margin

-257.98% · CORE · VALID

R&D intensity100thOwn-history percentile · N=8
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

66.22% · OPTIONAL · VALID

SBC intensity50thOwn-history percentile · N=8
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

15.43% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History16 statesHistory building
Sep 30, 20220/7 normalizedLevel 3Dec 31, 20220/7 normalizedLevel 3Mar 31, 20230/7 normalizedLevel 3Jun 30, 20230/7 normalizedLevel 3Sep 30, 20230/8 normalizedLevel 3Dec 31, 20230/8 normalizedLevel 3Mar 31, 20240/8 normalizedLevel 3Jun 30, 20240/8 normalizedLevel 3Sep 30, 20247/8 normalizedLevel 3Dec 31, 20247/8 normalizedLevel 3Mar 31, 20256/8 normalizedLevel 3Jun 30, 20256/7 normalizedLevel 3Sep 30, 20257/7 normalizedLevel 3Dec 31, 20257/7 normalizedLevel 3Mar 31, 20267/7 normalizedLevel 3Jun 30, 20267/7 normalizedLevel 3
Period transition

What moved in the state?

Capex Intensity Decreased
Previous
0.24%
Current
0.00%
Delta
-0.24%
Cash Generation Decreased
Previous
-67.69%
Current
-222.34%
Delta
-154.65%
Growth Decreased
Previous
177.89%
Current
-17.90%
Delta
-195.80%
Inventory Pressure Increased
Previous
297.55%
Current
598.40%
Delta
300.85%
Margin Decreased
Previous
52.39%
Current
35.37%
Delta
-17.01%
Profitability Decreased
Previous
-82.50%
Current
-257.98%
Delta
-175.48%
R And D Intensity Increased
Previous
22.89%
Current
66.22%
Delta
43.33%
Sbc Intensity Increased
Previous
0.00%
Current
15.43%
Delta
15.43%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Transitioned To · FEED Fundamental State →Has State · ENvue Medical, Inc. →Transitioned To · FEED Fundamental State →Transitioned To · FEED CAPEX_INTENSITY_DECREASED →Transitioned To · FEED CASH_GENERATION_DECREASED →Transitioned To · FEED GROWTH_DECREASED →Transitioned To · FEED INVENTORY_PRESSURE_INCREASED →Transitioned To · FEED MARGIN_DECREASED →Transitioned To · FEED PROFITABILITY_DECREASED →Transitioned To · FEED R_AND_D_INTENSITY_INCREASED →Transitioned To · FEED SBC_INTENSITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.